Microsoft launches new Copilot Mode in Edge as AI reignites browser competition
AI is bringing the browser wars back.
Microsoft is launching a new AI-powered 'Copilot Mode' for its Edge browser, part of a broader industry push toward AI-enabled browsing. The company is aiming to keep pace with a new wave of startups and claw back market share in a space dominated by Google Chrome in recent years.
Available starting today, the experimental, opt-in Copilot Mode offers a simplified tab page with a unified input box for chat, search, and navigation. With user permission, the new mode will be able to take into account all open tabs to inform its responses to user prompts.
Microsoft says future updates will let Copilot Mode take more advanced actions — book reservations, remember tasks and organize browsing history into topic-based 'journeys.'
The Redmond company dominated the browser market for years with Internet Explorer, before losing its lead to Chrome amid the rise of mobile browsing and the shift to faster, more streamlined alternatives. As of June, Edge holds just under 5% of the global browser market, compared to Chrome's dominant 68%, according to Statcounter.
Google has rolled out an AI Mode for search, and begun integrating its Gemini AI assistant directly into the web browser.
In the meantime, a new wave of AI-enabled browsers is emerging, such as Arc's Dia, Perplexity's Comet, and Opera's Aria AI mode. Microsoft partner OpenAI is also reportedly developing its own browser, leveraging the popularity of ChatGPT — potentially creating another strong rival in the market.
Copilot Mode is available starting today as an opt-in feature for Edge users on Windows and Mac. Microsoft says it will be free for a limited time, but it hasn't specified how long the free period will last, or what changes might follow. Users can visit aka.ms/copilot-mode to opt in.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on Valueinvesting subreddit by bluespacecolombo. In this article, we will summarize the bulls' thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $27.61 as of July 28th. A scientist in a laboratory coat looking into a microscope at human bone regeneration samples. Ultragenyx Pharmaceutical (RARE) has seen its share price halve in just two weeks, largely due to a halted trial and an FDA rejection, but the market appears to have overreacted. The company's Phase 3 trial for setrusumab, a potential blockbuster therapy for a rare bone disease, failed to meet an early 'stop-for-efficacy' milestone, yet the study remains on track, with safety intact and final results expected in late 2025 under less stringent endpoints. Meanwhile, the FDA issued a complete response letter for another gene therapy candidate, citing manufacturing issues rather than safety or efficacy concerns. The program remains viable, with a resubmission expected once production adjustments are made. Despite these setbacks, Ultragenyx continues to generate meaningful revenue, posting $139 million in Q1 and guiding for over $640 million in 2025, and maintains a robust cash position of around $560 million, with management projecting lower cash burn. Beyond setrusumab, the company's pipeline is well diversified, featuring DTX401, a gene therapy for glycogen storage disease that met Phase 3 goals and is slated for FDA submission this year, as well as an advanced Angelman syndrome program in Phase 3. None of the recent regulatory or clinical updates involved failures of safety or efficacy, leaving the scientific foundation of the pipeline intact. Analysts' average price targets remain near $100, implying a potential threefold upside from the current ~$26 level. With solid fundamentals, multiple near-term catalysts, and a temporarily depressed valuation, Ultragenyx represents a compelling contrarian opportunity as panic-driven selling unwinds. Previously we covered a bullish thesis on Capricor Therapeutics, Inc. (CAPR) by androidmj in March 2025, which highlighted the upcoming FDA decision on Deramiocel, strong financial backing, and significant upside on approval. The company's stock has depreciated about 46.32% since then as the thesis has yet to play out. The thesis still stands given CAPR's cash runway and de-risked catalyst. bluespacecolombo shares a similar view on the biotech space but emphasizes Ultragenyx's diversified pipeline, overreaction-driven selloff, and near-term catalysts. Ultragenyx Pharmaceutical Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held RARE at the end of the first quarter which was 57 in the previous quarter. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 minutes ago
- Yahoo
Tesla Offers Musk $30 Billion to Stay--With Strings Attached
Tesla (NASDAQ:TSLA) just handed CEO Elon Musk a massive new stock awardworth around $30 billiondesigned to keep him anchored at the helm while the company weathers legal battles and business headwinds. The package includes 96 million shares at a $23.34 exercise price, and it only kicks in if Musk stays in a senior leadership role for another two years. It's a stopgap move while the board appeals a court decision that voided his original 2018 compensation plan. That plan, once pegged at $56 billion, has become a flashpoint for investors and governance advocates alike. The interim award signals Tesla's intent to keep Musk focused during a volatile phase for the business. Tesla's board calls this a good faith gestureand timing matters. After a tough first half marked by declining sales, falling revenue, and a 25% YTD drop in share price, the company is leaning heavily on Musk's leadership to navigate what it describes as a critical inflection point. According to Wedbush analyst Dan Ives, the new agreement helps remove a lingering cloud over the stock and likely cements Musk's role for the foreseeable future. The board is also developing a longer-term pay structure, to be voted on at the November 6 shareholder meeting. But leadership retention isn't the only thing on the line. Musk's attention has been split across multiple venturesSpaceX, xAI, X Corp, Neuralink, The Boring Companyand his recent political entanglements haven't helped. The board acknowledges these distractions but says Musk remains central to Tesla's ability to attract and retain talent. Meanwhile, Tesla is trying to build momentum around its new robotaxi program, launched in Austin, which could be a long-term growth lever. Whether this compensation reset keeps Musk focused on Teslaor just buys timeis what investors will be watching next. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
How to get free Burger King Whoppers for 6 days straight
Burger King and Walmart+ lovers to the front. The companies are offering a deal that'll give customers a free Whopper with a $1 purchase for six days straight. The deal is only available for shoppers who are members of both Walmart+ and Burger King Royal Perks programs, a Burger King representative told USA TODAY via email. The deal will run from Tuesday, Aug. 5, to Monday, Aug. 11. The special was announced to celebrate the one-year anniversary of Walmart and Burger King's first-ever joint promotion, launched last summer. Last year's deal gave Walmart+ members 25% off any Burger King digital order every day, as well as a free Whopper every three months starting in September 2024. Here's what to know to get the deal: Read more: Walmart+ members get 25% off Burger King, free Whoppers in new partnership How can I get my free Whopper this week? Guests can take advantage of the deal by linking their Burger King Royal Perks and Walmart+ accounts. To link your accounts: Make sure the Burger King app is downloaded on your device. Download the Walmart app and sign in. Or, log in at Go to "Account." Select "Walmart+ membership." Find the Burger King Savings benefit and select "Get started." The Burger King app should open automatically. Select the "Link accounts" button. Once customers have linked their Walmart+ and Burger King accounts, they can redeem the offer by: ordering in-store using their 6-digit code, opening the Burger King app, going to the 'Offers' tab and activating the offer, and logging in at to place an order. Did someone say diner? Elon Musk fans flock to new Tesla Diner Are there any restrictions? The deal is not available during breakfast hours except at select locations, and customers can only get one free Whopper per account each day, Burger King said. The offer cannot be used with delivery orders. More on Walmart+ and Burger King Royal Perks Walmart+ is Walmart's delivery program that starts at $12.95 a month or $98 annually. The program has student and government assistance eligibility, per the company's website. Royal Parks is Burger King's free rewards program that allows customers to earn points, or crowns, for every $1 spent on eligible transactions. Customers can then cash in the crowns for free menu items. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@ This article originally appeared on USA TODAY: Got Walmart+ and Burger King Royal Perks? Get a free Whopper.
